A Ganoderma lucidum polysaccharide F31 alleviates hyperglycemia through kidney protection and adipocyte apoptosis

Int J Biol Macromol. 2023 Jan 31:226:1178-1191. doi: 10.1016/j.ijbiomac.2022.11.231. Epub 2022 Nov 25.

Abstract

In this paper, we reported an excellent hypoglycemic effect of a Ganoderma lucidium polysaccharide F31 with efficacies between 45 and 54 %, approaching to that of liraglutide (52 %). Significantly, F31 reduced the body weight gains and food intakes. F31 decreased 4 key compounds, consisting of adenosine, adenosine, galactitol and glycerophosphocholine and elevated 8 key compounds, including arginine, proline, arachidonic acid, creatine, aspartic acid, leucine, phenylalanine and ornithine, which protected kidney function. Also, apoptosis was promoted by F31 in epididymal fat through increasing Caspase-3, Caspase-6 and Bax and decreasing Bcl-2. On 3 T3-L1 preadipocyte cells, F31 induced early apoptosis through reducing mitochondrial membrane potential. Finally, a molecular docking was performed to reveal a plausible cross-talk between kidney and epididymal fat through glycerophosphorylcholine-Bax axis. Overall, F31 alleviated hyperglycemia through kidney protection and adipocyte apoptosis in db/db mice. This work may provide novel insights into the hypoglycemic activity of polysaccharides.

Keywords: Adipocyte apoptosis; Ganaderma lucidum; Hypoglycemia; Kidney protection; Metabolomics; Polysaccharides.

MeSH terms

  • Adipocytes
  • Animals
  • Apoptosis
  • Ganoderma*
  • Hyperglycemia* / drug therapy
  • Hypoglycemic Agents / pharmacology
  • Kidney
  • Mice
  • Molecular Docking Simulation
  • Polysaccharides / pharmacology
  • Reishi*
  • bcl-2-Associated X Protein

Substances

  • bcl-2-Associated X Protein
  • Polysaccharides
  • Hypoglycemic Agents